35 search results for: mechanism of disease

Under the Itchy Surface: The Insidious, Cumulative Burden <b>of</b> Type 2 Inflammation in AD
Dermatology
Under the Itchy Surface: The Insidious, Cumulative Burden of Type 2 Inflammation in AD
expert video

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses the systemic nature of atopic dermatitis (AD) and how the disease burden extends beyond the skin. Through the lens of cumulative life course impairment, Dr. Simpson goes on to explore how persistent type 2 inflammation in AD may drive both atopic and nonatopic comorbidities, emphasizing the potential importance of early and effective therapeutic intervention to alter disease progression

View more
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study <b>of</b> Pediatric Patients With AD and Type 2 Comorbidities
Dermatology
Dupilumab Reduces Total IgE and Allergen-Specific IgE in a Real-World Study of Pediatric Patients With AD and Type 2 Comorbidities
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares discusses evidence demonstrating that dupilumab reduces both total and allergen-specific IgE in pediatric patients with atopic dermatitis and comorbid allergic diseases, underscoring the role of IL-4/IL-13 blockade in modulating B-cell activity.

View more
CLCI in Atopic Dermatitis Infographic
Dermatology
CLCI in Atopic Dermatitis Infographic
Infographic

This infographic highlights how uncontrolled moderate‑to‑severe atopic dermatitis (AD) can lead to Cumulative Life Course Impairment (CLCI) by contributing to ongoing physical, psychological, and social burdens such as itch and sleep loss, impaired bone growth and mental health challenges. It emphasizes the importance of early and effective disease control to help reduce long‑term impact on patients.

View more
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
Dermatology
How Does Protective Type 2 Immunity Become Harmful Type 2 Inflammation?
expert video

In this video from the March 2025 ADVENT symposium in Orlando, Florida, Dr. Eric Simpson discusses how protective type 2 immunity can become dysregulated, leading to harmful type 2 inflammation. The associated inflammatory process can contribute to the pathophysiology of several dermatological diseases, including AD, PN, CSU, and BP.

View more
Differential Effects <b>of</b> Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD
Dermatology
Differential Effects of Dupilumab and JAK Inhibitors on CCL17 (TARC) in Patients With AD
expert video

In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Oscar Palomares compares the effects of biologics and JAK inhibitors on the biomarker CCL17 (TARC) in atopic dermatitis.

View more